Q-omics provides the consensus-scored USP34 profile across patient tissues and cancer cell-line models. USP34 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, USP34 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, USP34 protein abundance shows 23,025 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, THCA, and GBM as cancer lineages where USP34 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for USP34 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes USP34 survival associations across molecular data types. USP34 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (12) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible USP34 RNA expression–survival associations across cancer types. High USP34 expression shows unfavorable associations in ACC, MESO and CESC, but favorable associations in KIRC, SCLC and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for USP34 RNA expression.
This table summarizes USP34 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for USP34. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. USP34 shows lower tumor expression in THCA, KICH and KIRC and higher tumor expression in HNSC, LUSC and CHOL. The THCA box plot shows higher USP34 RNA expression in normal versus tumor tissue (log2 FC = −0.736, t-test p < 0.001).
This table shows molecular features associated with USP34 in patient tissues and cancer cell lines. In patient samples, USP34 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, USP34 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
